

# **Multiplexed phosphoproteomic profiling using titanium dioxide and immuno-affinity enrichments reveals complementary phosphorylation events**

**Anthony P Possemato<sup>1‡</sup>, Joao A Paulo<sup>2‡</sup>, Daniel Mulhern<sup>1</sup>, Ailan Guo<sup>1</sup>, Steven P Gygi<sup>2</sup>, and Sean A Beausoleil<sup>1¶</sup>**

<sup>1</sup> Bluefin Biomedicine, Beverly, MA 01915, United States

<sup>2</sup> Department of Cell Biology, Harvard Medical School, Boston, MA 02115, United States

‡ These authors contributed to this work equally


¶ To whom correspondence should be addressed: [sbeausoleil@bluefinbiomed.com](mailto:sbeausoleil@bluefinbiomed.com)

## **Table of contents**


<b>Supplemental Figure 1</b>	<b>S-2</b>
<b>Supplemental Figure 2</b>	<b>S-3</b>
<b>Supplemental Figure3</b>	<b>S-4,5</b>

Supplemental Figure 1

A)



B)




**Supplemental Figure 1: Analysis of phosphopeptide enrichment.** A) Phosphopeptide enrichment for each of the 24 fractions using the TiO<sub>2</sub> method. B) Phosphopeptide enrichment for each IAP (replicate 1 and 2).

Supplemental Figure 2


A)

	Kinases
TiO <sub>2</sub>	96
IAPs	119

B)




C)



**Supplemental Figure 2: Kinases identified by TiO<sub>2</sub> and IAP enrichments** A) Tally of kinases identified with each enrichment strategy. B) Venn diagram of corresponding overlap. C) Venn diagrams for Tyrosine, CAMK and CMGC kinases for each enrichment strategy.



### C) Staurosporine



**Supplemental Figure 3: Sequence logos for phosphorylation sites.** PhosphoSitePlus (<http://www.phosphosite.org>) motif analysis (38) of quantified phosphorylation events inhibited following treatment with A) BEZ-235, B) GSK 1120212, and C) Staurosporine. Sequences were centered at the phosphorylated residue and extended six amino acids on each side, thereby resulting in a 13-amino acid long motif for each phosphorylation site.